Results 151 to 160 of about 3,018 (196)

Emerging Role of Biologic Drugs Targeting IL-17 and IL-23: Pityriasis Rubra Pilaris. [PDF]

open access: yesLife (Basel)
Potestio L   +8 more
europepmc   +1 more source

Loss-of-function mutations in Keratin 32 gene disrupt skin immune homeostasis in pityriasis rubra pilaris. [PDF]

open access: yesNat Commun
Shi P   +23 more
europepmc   +1 more source

Pityriasis rubra pilaris secondary to viral infection

open access: yesPrzegląd Dermatologiczny
Kacper Pawlik   +4 more
doaj   +1 more source

Guselkumab for Pityriasis Rubra Pilaris and Dysregulation of IL-23/IL-17 and NFkB Signaling: A Nonrandomized Trial.

open access: yesJAMA Dermatol
Velasco RC   +7 more
europepmc   +1 more source

PITYRIASIS RUBRA PILARIS

Archives of Dermatology, 1971
To the Editor.— Regarding "Pityriasis Rubra Pilaris: Prolonged Treatment With Methotrexate" by Knowles and Chernosky in theArchives( 102 :603. 1970), and in view of some work I have done with vitamin A and reported cases of successful therapy with vitamin A, I would like to make these comments.
openaire   +4 more sources

Pityriasis rubra pilaris

Der Hautarzt, 2004
Pityriasis rubra pilaris (PRP) is a rare papulosquamous disease with typical onset during the first and fifth decades. The skin disorder normally starts on the scalp and spreads caudally within a few weeks. It often results in a generalized erythroderma with sharply demarcated islands of sparing ("nappes claires"). A 65-year-old patient with severe PRP
S, Artik   +4 more
openaire   +3 more sources

Home - About - Disclaimer - Privacy